

phys

Continuous Wearable Monitoring Analytics to Improve Outcomes\_ in Heart Failure: Vanguard Phase Results and Study Design of the Randomized Phase of LINK-HF2 multicenter study

<u>K.Sideris</u>, MD<sup>1,2</sup>, J.Stehlik, MD, MPH<sup>1,2</sup>, C.Schmalfuss, MD<sup>3</sup>, T.Hanff, MD, MSCE<sup>1,2</sup>, R.Schofield, MD, FACC<sup>3</sup>, M.Pipke, JD<sup>4</sup>,K.Larimer, PhD<sup>4</sup>, C.Davis, MPH<sup>3</sup>, B.Beauchamp, BS<sup>3</sup>, H.Hanson, BS, CRC1, J.M.Butler, PhD<sup>1,2</sup> C.Weir, PhD<sup>1,2</sup>

<sup>1</sup>George E. Wahlen VA Medical Center, Salt Lake City, UT; <sup>2</sup> University of Utah School of Medicine, Salt Lake City, UT; <sup>3</sup>Malcom Randall VA Medical Center, Gainesville, FL; <sup>4</sup>PhysIQ, Inc. Chicago

**<u>Background</u>**: LINK-HF study has shown that multivariate physiological telemetry from a wearable sensor combined with machine learning can provide accurate early detection of impending heart failure (HF) hospitalization.

## Challenges

- Over-Alerting
- Time needed for data review
- Staffing






Whether early intervention based on predictive data generated through artificial intelligence (AI) analytical methods could improve outcomes in HF is not known.

Methods: The LINK-HF2 study consists of two phases. The completed, non-randomized vanguard phase enrolled 27 patients with HF at 2 VA sites, and the ongoing main randomized phase will enroll 240 patients at 5 VA sites. The predictive AI system used in this study is a cloud-based analytic platform that generates a multivariate change index (MCI) to identify changes in observed physiological patterns that deviate from the expected normal behavior.


Deference to other providers

## Protocol Adjustments

- Refinement of the algorithmic response to predictive alerts
- Expansion of clinician education
- Improved education of study subjects on the meaning of predictive notifications
- Aggregating repeated MCI alerts within 72 hours into a single event Notification



team.



**Results**: vanguard phase, comprehensive the implementation program was developed and examined non-invasive remote integration of monitoring and subsequent algorithmic response to the clinical workflow. Clinicians responded to notifications within 24 hours in 95% of instances and clinical action was taken in 25% of instances. Randomized phase: Initiated in 01/2022. 50 out of the projected 240 subjects with HF have been enrolled. Subjects will be fitted with the non-invasive monitor and randomized to either an active arm, in which notifications will be communicated to clinical providers and followed by an algorithmic response, or to a control arm where notifications will not be communicated to the clinical

Outcomes

•HF hospitalization

All-cause hospitalization

Hospitalization length

•Health-related quality of life (KCCQ12, VAS) •Cost of medical care

**<u>Conclusions</u>:** LINK-HF2 study will provide clinical utility data for and approach where algorithmic response will be taken to AI predictive analytics derived from multivariate physiological telemetry from a wearable sensor